Skip to main content
. 2024 Jul 22;115(10):3333–3345. doi: 10.1111/cas.16292

FIGURE 5.

FIGURE 5

YAP–MCL‐1 axis‐induced tolerant cells with a combination of lazertinib and AXL inhibitor in EGFR‐mutant NSCLC cells. (A) PC‐9 and HCC4011 cells were treated with lazertinib (100 nmol/L), ONO7475 (100 nmol/L), or a combination of lazertinib and ONO7475 for 48 h. The cells were lysed, and the indicated proteins were detected using western blotting. (B) PC‐9 and HCC4011 cells were treated with nonspecific control siRNA or YAP‐specific siRNA and incubated with lazertinib (100 nmol/L) or a combination of lazertinib and ONO7475 (100 nmol/L) for 48 h. The cells were lysed, and the indicated proteins were detected using western blotting. (C) PC‐9 and HCC4011 cells were treated with nonspecific control siRNA or YAP‐specific siRNAs and incubated with lazertinib (100 nmol/L) or a combination of lazertinib and ONO7475 (100 nmol/L) for 72 h. Cell growth was determined using MTT assays. *p < 0.05. (D) PC‐9 and HCC4011 cells were treated with lazertinib (100 nmol/L) or a combination of lazertinib and ONO7475 (100 nmol/L) for 48 h. Proteins were fractured into the nucleus and cytoplasm using NE‐PER™ Nuclear and Cytoplasmic Extraction Reagents. (E) Immunofluorescence showing nuclear localization of YAP in EGFR‐mutant NSCLC cells exposed to lazertinib (100 nmol/L) or a combination of lazertinib and ONO7475 (100 nmol/L) for 48 h. Scale bars, 20 μm. (F) qPCR of MCL‐1 in PC‐9 and HCC4011 cells treated with nonspecific control siRNA or YAP‐specific siRNAs and incubated lazertinib (100 nmol/L) or a combination of lazertinib and ONO7475 (100 nmol/L) for 48 h. *p < 0.05.